The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ADXS Detailed Price Forecast - CNN Money||View ADXS Detailed Summary - Google Finance|
|View ADXS Detailed Summary - Yahoo! Finance||View ADXS Stock Research & Analysis - Zacks.com|
|View ADXS Trends & Analysis - Trade-Ideas||View ADXS Major Holders - Barrons|
|View ADXS Call Transcripts - NASDAQ||View ADXS Breaking News & Analysis - Seeking Alpha|
|View ADXS Annual Report - CompanySpotlight.com||View ADXS OTC Short Report - OTCShortReport.com|
|View ADXS Fundamentals - TradeKing||View ADXS SEC Filings - Bar Chart|
|View Historical Prices for ADXS - The WSJ||View Performance/Total Return for ADXS - Morningstar|
|View the Analyst Estimates for ADXS - MarketWatch||View the Earnings History for ADXS - CNBC|
|View the ADXS Earnings - StockMarketWatch||View ADXS Buy or Sell Recommendations - MacroAxis|
|View the ADXS Bullish Patterns - American Bulls||View ADXS Short Pain Metrics - ShortPainBot.com|
|View ADXS Stock Mentions - StockTwits||View ADXS Stock Mentions - PennyStockTweets|
|View ADXS Stock Mentions - Twitter||View ADXS Investment Forum News - Investor Hub|
|View ADXS Stock Mentions - Yahoo! Message Board||View ADXS Stock Mentions - Seeking Alpha|
|View Insider Transactions for ADXS - SECform4.com||View Insider Transactions for ADXS - Insider Cow|
|View ADXS Major Holdings Summary - CNBC||View Insider Disclosure for ADXS - OTC Markets|
|View Insider Transactions for ADXS - Yahoo! Finance||View Institutional Holdings for ADXS - NASDAQ|
|View ADXS Stock Insight & Charts - FinViz.com||View ADXS Investment Charts - StockCharts.com|
|View ADXS Stock Overview & Charts - BarChart||View ADXS User Generated Charts - Trading View|
Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting
Posted on Tuesday November 06, 2018
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC). The poster, entitled “Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy,” evaluated the impact of Lm-based immunotherapy on the activation of NK cells in a murine model of human papillomavirus (HPV)-associated tumors.
Advaxis Provides Update on Clinical Pipeline
Posted on Friday November 02, 2018
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV). The current trial design has a planned sample size of 450 subjects to maintain adequate statistical power over a broader range of survival outcomes, as well as a pre-planned interim analysis (IA) of safety and efficacy. The Company anticipates that over the next couple of months it will finalize the redesign of the trial and review it with the U.S. Food and Drug Administration (FDA).
Advaxis to Host Business Update Conference Call on November 2, 2018
Posted on Friday October 26, 2018
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.
Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence
Posted on Thursday October 18, 2018
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.